Program
Voriconazole
Also written as “voriconazole”, “voriconazole (Vfend)” and “oral voriconazole”.
Its studies are mostly in Aspergillosis · Mycoses · Invasive Fungal Infections · Candidemia · Candidiasis, led by 3 companies.
Drug pageVoriconazole: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 200 open or running | phase 4since Aug 31, 2005 | Aug 25, 2005 | none ahead |
| Yung Shin Pharm. Ind.its history only | 20 open or running | phase 4since Sep 21, 2016 | Sep 21, 2016 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 1since Dec 13, 2015 | Dec 13, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Chong Kun Dang Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2015First study: phase 1 study in AspergillosisFirst studyNCT02631954 · 24 enrolled · Korea, Republic of
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
The one study Chong Kun Dang Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02631954Aspergillosis · Korea, Republic of | 1 | Completed | Oct 2015 | 24 |
How it is read
Names in the registry
- “Voriconazole”, 13 entries
- “voriconazole”, 7 entries
- “voriconazole (Vfend)”, 3 entries
- “oral voriconazole”, 1 entry
- “Vaway”, 1 entry
Conditions, from the studies’ own filings
- Aspergillosis, 7 studies
- Mycoses, 3 studies
- Invasive Fungal Infections, 3 studies
- Candidemia, 3 studies
- Candidiasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.